Model Medicines is a preclinical stage AI/ML pharmtech company. The company has leveraged our drug and disease agnostic CHEMprintTM drug discovery platform to discover 70+ compounds for 10+ targets covering infectious disease, oncology and GI indications, with industry leading hit rates. Model recently submitted a PIND regulatory filing to the FDA for its lead compound, MDL-001, making it one of the 1st companies in the world to discover a drug using AI/ML and develop it to a regulatory filing status.
Model announced potential best-in-class preclinical data for our orally available lead therapeutic against COVID-19, in partnership with Scripps Research and Mount Sinai. These results demonstrated the company's ability to create a potential best-in-class therapeutic in months for a fraction of the cost associated with traditional drug discovery using our platform. As a result, Model has been accepted into NIH/NIAID's APP program to accelerate the MDL-001's development.
Model announced potential best-in-class preclinical data for our orally available lead therapeutic against COVID-19, in partnership with Scripps Research and Mount Sinai. These results demonstrated the company's ability to create a potential best-in-class therapeutic in months for a fraction of the cost associated with traditional drug discovery using our platform. As a result, Model has been accepted into NIH/NIAID's APP program to accelerate the MDL-001's development.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2019
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
MDL-001 - A Clinically Safe, Orally Available, Extended Half-life, Broad Spectrum Antiviral
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
70+
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
